These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 10678789

  • 1. High-dose intravenous fluoroquinolones in the treatment of severe infections.
    Modai J.
    J Chemother; 1999 Dec; 11(6):478-85. PubMed ID: 10678789
    [Abstract] [Full Text] [Related]

  • 2. Do we need an intravenous fluoroquinolone?
    Maddix DS, Warner L.
    West J Med; 1992 Jul; 157(1):55-9. PubMed ID: 1413744
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H, Hayakawa I, Akimoto T.
    Yakushigaku Zasshi; 2003 Jul; 38(2):161-79. PubMed ID: 15143768
    [Abstract] [Full Text] [Related]

  • 6. [Fluoroquinolones--a new and important group of antimicrobial agents].
    Sander J.
    Tidsskr Nor Laegeforen; 1992 Jan 30; 112(3):346-9. PubMed ID: 1553674
    [Abstract] [Full Text] [Related]

  • 7. Avoiding fluoroquinolone resistance. Strategies for primary care practice.
    Stratton CW.
    Postgrad Med; 1997 Mar 30; 101(3):247-50, 255. PubMed ID: 9074562
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Overview of the fluoroquinolone antibiotics.
    Just PM.
    Pharmacotherapy; 1993 Mar 30; 13(2 Pt 2):4S-17S. PubMed ID: 8386356
    [Abstract] [Full Text] [Related]

  • 10. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.
    Schentag JJ.
    J Chemother; 1999 Dec 30; 11(6):426-39. PubMed ID: 10678784
    [Abstract] [Full Text] [Related]

  • 11. The fluoroquinolones.
    Walker RC, Wright AJ.
    Mayo Clin Proc; 1991 Dec 30; 66(12):1249-59. PubMed ID: 1749294
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
    Schentag JJ, Birmingham MC, Paladino JA, Carr JR, Hyatt JM, Forrest A, Zimmer GS, Adelman MH, Cumbo TJ.
    Semin Respir Infect; 1997 Dec 30; 12(4):278-93. PubMed ID: 9436955
    [Abstract] [Full Text] [Related]

  • 14. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ, Liu HY, Lin YC, Sun KL, Chun CL, Hsueh PR.
    Int J Antimicrob Agents; 2010 Mar 30; 35(3):261-4. PubMed ID: 20045290
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The impact of fluoroquinolones use on antibiotic resistance in an intensive care burn department.
    Thabet L, Memmi M, Turki A, Messadi AA.
    Tunis Med; 2010 May 30; 88(5):297-300. PubMed ID: 20517823
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.